Marathon Pharmaceuticals announced positive results from the Phase 3 study of Zingo (lidocaine hydrochloride monohydrate) for the reduction of venous access pain in pediatric patients.
All articles by Lea Eslava-Kim, PharmD
Latest News Your top articles for SundayFor More Personalized News
Haymarket Medical NetworkTop Picks
Continuing Medical Education (CME/CE) Courses